Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA

View through CrossRef
Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASNO we reported PFS.Now we reporte update about OS from our single center study. METHODS From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study. Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields. The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves). Secondary endpoint was the influences about KPS score in PFS and OS. RESULTS The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.1 years (12-68). Gross total resection (GTR) was performed in eighteen patients. Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter. Followed up until January 2024, the median PFS was 13.3 months [95% CI: 11.33-15.2] with TTFields combined and 4.0 months (95% CI, 3.8-4.4) without TTFields treatment in EF-14.Median OS was 26.53 months [95% CI:19.47-33.57] with TTFields and 16.0 months (95% CI, 3.8-4.4) control in EF-14. In the KPS stratification, OS was 27.5 months (95% CI: 22.95-32.1) vs 4.3 months (95% CI: 0-11.2), p=0.0001. The OS of patients with concurrent chemoradiotherapy combined with TTFields vs. without concurrent chemoradiotherapy combined with TTFields was 26.5 months (95% CI: 24.33-28.7) vs 21.2 (95% CI: 3.1-39.3) months, p=0.59. CONCLUSIONS TTFields therapy is an effective treatment for HGG. In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.
Title: QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA
Description:
Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy.
The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China.
In 2023 ASNO we reported PFS.
Now we reporte update about OS from our single center study.
METHODS From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study.
Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields.
The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves).
Secondary endpoint was the influences about KPS score in PFS and OS.
RESULTS The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.
1 years (12-68).
Gross total resection (GTR) was performed in eighteen patients.
Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter.
Followed up until January 2024, the median PFS was 13.
3 months [95% CI: 11.
33-15.
2] with TTFields combined and 4.
0 months (95% CI, 3.
8-4.
4) without TTFields treatment in EF-14.
Median OS was 26.
53 months [95% CI:19.
47-33.
57] with TTFields and 16.
0 months (95% CI, 3.
8-4.
4) control in EF-14.
In the KPS stratification, OS was 27.
5 months (95% CI: 22.
95-32.
1) vs 4.
3 months (95% CI: 0-11.
2), p=0.
0001.
The OS of patients with concurrent chemoradiotherapy combined with TTFields vs.
without concurrent chemoradiotherapy combined with TTFields was 26.
5 months (95% CI: 24.
33-28.
7) vs 21.
2 (95% CI: 3.
1-39.
3) months, p=0.
59.
CONCLUSIONS TTFields therapy is an effective treatment for HGG.
In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.

Related Results

Abstract 92: Increasing TTFields treatment efficacy by targeting G2 cell cycle checkpoint
Abstract 92: Increasing TTFields treatment efficacy by targeting G2 cell cycle checkpoint
Abstract Introduction; Tumor Treating Fields (TTFields) is a novel non-invasive anticancer treatment modality utilizing alternating electric fields. TTFields is FDA ...
Abstract 2094: Prostaglandin E receptor 3 mediates resistance to tumor treating fields in glioblastoma cells
Abstract 2094: Prostaglandin E receptor 3 mediates resistance to tumor treating fields in glioblastoma cells
Abstract Glioblastoma (GBM) is the most common and deadliest malignant brain cancer in adults despite surgery and aggressive chemoradiotherapy. Tumor Treating Fields...
Abstract 1833: Tumor treating fields induce DNA damage and apoptosis in medulloblastoma
Abstract 1833: Tumor treating fields induce DNA damage and apoptosis in medulloblastoma
Abstract Medulloblastoma (MB) is the most common malignant brain tumor in children and accounts for approximately 20% of all pediatric central nervous system tumors....
Abstract 2018: Tumor treating fields (TTFields) disrupt cancer cell invasion by impacting cell-ECM traction forces
Abstract 2018: Tumor treating fields (TTFields) disrupt cancer cell invasion by impacting cell-ECM traction forces
Abstract Introduction: Tumor Treating Fields (TTFields) are an anti-cancer treatment that use low intensity, alternating electric fields. Anti-mitotic treatment effe...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Forschungsfortschritt zum Mechanismus der durch TTFields induzierten Antitumor-Immunantwort
Forschungsfortschritt zum Mechanismus der durch TTFields induzierten Antitumor-Immunantwort
Tumortherapiefelder (TTFields), eine biophysikalische Therapietechnologie, die elektrische Wechselfelder zur Hemmung der Tumorproliferation einsetzt, wurden von der US-amerikanisch...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract Introduction Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
1H-MR spectroscopy in grading of cerebral glioma: A new view point, MRS image quality assessment
1H-MR spectroscopy in grading of cerebral glioma: A new view point, MRS image quality assessment
Background Noninvasive preoperative prediction of histological grading is essential for clinical management of cerebral glioma. Purpose This study aimed to investigate the associat...

Back to Top